Induction of tolerance to allogeneic MHC antigens has been a goal in the field of transplantation because it would reduce or eliminate the need for generalized immunosuppression. Although encouraging results have been obtained in experimental models by exposing recipient thymus to donor cells before transplantation, donor cells are not typically available at that time, and the donor antigens responsible for the effect are poorly defined. In the present study, thymic tolerance was demonstrated without using donor cells. Recipient thymus was injected before transplantation with autologous myoblasts and myotubes that were genetically modified to express allogeneic donor-type MHC class I antigen. Donor-specific unresponsiveness was induced to a completely MHC-disparate liver transplant and to a subsequent donor-type cardiac allograft, but not a third-party allograft. In vitro, recipient CTL demonstrated a 10-fold reduction in killing of donor cells, but not of third-party cells. Our results demonstrate: (1) that recipient muscle cells can be genetically engineered to induce donor-specific unresponsiveness when given intrathymically, and (2) transfected recipient cells expressing only donor MHC class I antigen can induce tolerance to a fully allogeneic donor.
In most transplant models of thymic tolerance, thymic exposure to donor cells has occurred several days or weeks before organ transplantation (4-7). This approach has limited clinical potential because of the absence of appropriate donor cells before donor organ availability. More importantly, it is not known which donor antigens are necessary or sufficient for tolerance induction. In the present study, we have used a strategy for producing thymic tolerance in a rat model that avoids the requirement of donor cells and allows the study of individual donor antigens using genetically altered recipient cells. We demonstrate the efficacy of intrathymic administration of autologous plasmid-transfected myoblasts (MB) and myotubes (MT) expressing donor MHC class I antigen to induce donor-specific unresponsiveness after liver transplantation in a fully allogeneic, high responder, rat strain combination. Using genetic manipulation, we show a tolerogenic effect with only MHC class I antigen.
MATERIALS AND METHODS
Preparation of the primary cell cultures. Primary muscle cell cultures were prepared as reported previously (10, 11). Briefly, minced soleus muscles from baby Lewis rats (3-5 days old) were dissociated in 0.17% trypsin and 0.09% collagenase in HBSS (pH 7.4, Gibco BRL, Gaithersburg, MD) for 55 min in an incubator-shaker at 37°C. After centrifuging, the dissociated cells were resuspended in 3 ml of com-plete media (containing 5% chick embryo extract [Gibco BRL], 15% horse serum, and 80% modified Eagle's media). MB were purified on a Percoll (Sigma Chemical, St. Louis, MO) gradient (20/60X) and 10 6 cells were placed into individual 35-mm gelatinized culture plates. The cells were then maintained in an incubator (37°C, humidified atmosphere of 5% C0 2 in air) with complete media that was changed every other day. After 4 days in culture, the cells spontaneously began to form MT that matured by 8 days in culture.
Plasmids and gene transfer procedures. Control plasmids used were-plasmid DNA encoding the firefly (Photinus pyraiis) luciferase gene (pRSVL) (12) and plasmid DNA encoding Escherichia coli 0-galactosidase (pRSVLac-Z) (13), under the control of the Rous sarcoma virus (RSV) long terminal repeat promoter. Plasmid DNA was purified by alkaline lysis, banded 2 times in a cesium chlorideethidium bromide gradient, dialyzed, and precipitated with ethanol before use.
The cDNA encoding the rat MHC class I antigen RTl.A a (14) was placed in a pcDNAl plasmid expression vector (pcRT.45) (15). The human immediate early CMV promoter and SV40 poly A and intron were used to enhance expression.
Both 2-day-old cultures containing MB and 4-day-old cultures containing MT were transfected as described previously (10). Briefly, plasmid DNA and Lipofectin reagent (Gibco BRL) (16) were diluted separately into 0.75 ml of Opti-MEM I reduced-serum medium (Gibco BRL). The 2 solutions were then mixed together drop by drop in a polystyrene tube. The DNA-Lipofectin complex solution was added to the primary muscle cells, which had been washed 3 times with Opti-MEM. After a 4-hr incubation, 1 ml of complete medium was added to each plate. Transfection plates were then maintained in the incubator at 37°C, 5% C0 2 .
Intrathymic transplantation. One day after DNA transfection, the MB and MT were harvested using Cell Lifters (Fisher Scientific, Pittsburgh, PA). (Fig. 1) , and by inspection of cell cultures using immunohistochemistry (Fig. 2, A and B Fig. 3) . Myosin-specific staining of the thymus 1 week after implantation confirmed the presence of myocytes containing myosin and myofilaments (Fig.  3, A, C, and E) . Myocytes were observed throughout the thymus, and some expressed RTl.A 3 (Fig. 3, B, D, and F) . transplants at least 60 days after their liver transplant without any additional immunosuppression. One heart was placed intra-abdominally, and the other anastomosed to the femoral vessels in the groin. In 2 cases, the ACI heart transplants survived indefinitely (> 100 days) without rejection, while the third-party WF hearts were rejected at 8 and 10 days. The third rat died 10 days after heart transplantation for technical reasons, but had rejected the WF heart at 8 days and the ACI heart was still beating just before death.
RESULTS

Transgenic
Histologic examination of multiple sections of ACI livers and hearts transplanted to tolerized Lewis recipients demonstrated no evidence of rejection at the time of death, which was > 100 days after transplantation. Third-party WF hearts underwent acute cellular rejection with a prominent lymphocytic infiltrate seen histologically.
Cytotoxic T cell frequency analysis. Compared with the normal Lewis rat response to ACI stimulators and targets, the tolerant Lewis rats demonstrated a markedly diminished CTL precursor frequency for ACI targets (Fig. 4A ), yet they maintained a normal CTL precursor frequency against thirdparty WF targets (Fig. 4B) In the present study, we achieved tolerance using primary cultured autologous cells expressing only allogeneic MHC class I antigen, and not MHC class II or non-MHC antigens. The results demonstrate that marked prolongation of graft survival, and in some cases donor-specific tolerance, is obtainable with a limited repertoire of donor antigens (only one) in a highly disparate rat strain combination. In fact, the strain combination was chosen specifically because it is a high-responder combination normally resulting in vigorous liver transplant rejection. Tolerance in this model was donor specific, as demonstrated by the results of the in vitro limiting dilution assay showing marked reduction in CTL precursor specific for ACI donor cells. Furthermore, the subsequent acceptance of the tolerized donor-strain heart transplant and rejection of the third-party donor heart transplant demonstrates in vivo evidence of donor-specific tolerance. The in vitro results were consistent with these, suggesting that the mechanism of thymic unresponsiveness in this model is due at least in part to a decrease in CTL responsiveness to the donor.
It is notable that intrathymic injection of MB/MT expressing only the reporter gene prolonged survival in a few animals. This effect might have been due to the nonspecific influence of thymic injection, since Staples et al. by transgenic cells may also be a factor. Behara et al. (22) have reported that thymic implantation of genetically modified fibroblasts do not lead to tolerization toward a soluble gene product (growth hormone). Failure to induce tolerance after thymic exposure to genetically modified fibroblasts may have been related to the level of gene expression in the thymus or the soluble nature of the gene product, since both of these parameters influence immune responsiveness.
The role of the liver transplant in testing tolerance induction with MHC class I antigen in this model may be substantial for 3 reasons. First, unresponsiveness to liver transplants is usually easier to achieve than unresponsiveness to either cardiac or renal transplants. For example, rat liver transplants can be substantially prolonged by intravenously administering blood cells expressing donor MHC class I antigen, whereas cardiac allograft survival is not prolonged by the same protocol (23). Second, MHC class I antigen may be more important for tolerance induction in liver transplant models (24) than in other organ models. Third, the acceptance of ACI cardiac allografts after ACI liver transplantation may be due in part to a tolerogenic effect of the transplanted liver. This phenomenon has been reported in a low-responder strain combination (25), although the mechanism is unknown.
Gene transfer to autologous cells provides a method to study the role of specific gene products in thymic tolerance without the interference of other donor antigens. Specific immunologic unresponsiveness to a fully MHC-disparate liver following presentation of only donor MHC class I in the thymus suggests that if manipulation of the recipient immune response favors unresponsiveness rather than rejection of one important target antigen, other existing MHC and
